• Select appropriate immunomodulatory therapy, have awareness of side effects, and when they may well require specialist care
• Respond urgently to the management challenge of these severe and often acute diseases and involve more specialist services where required.
BACKGROUND
In their classic description, PBC and AIH are two distinct autoimmune liver diseases, each with their own clinical, biochemical, immunological and histopathological features (Table 1) , as well as treatment response. In the majority of cases, distinguishing between a diagnosis of PBC and one of AIH is without strain but for a minority of patients who have features of more than one condition, either at the time of first presentation or over their disease course, the diagnostic process and treatment plan can be challenging. This is a broader reflection that many mechanisms underpinning liver and biliary injury in patients with autoimmune liver disease are shared. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
PRESENTATION
Patients with overlap syndromes can present in a number of different ways. Some may be identified at the time of diagnosis (the simultaneous presentation), whilst others have a diagnosis of one condition which is stable for a number of years before they develop features of another (the sequential presentation). In those with a simultaneous presentation, extra care needs to be taken when diagnosing overlap as this is most often a reflection of disease variation rather than a true overlap, and many would delay reaching such a diagnosis until after the dominant disease process is treated and a repeat evaluation is undertaken (case 1). The diagnosis in those with a sequential presentation is often much more straightforward and these patients are easier to characterise as having cross-over features. As is characteristic of classical AIH, some patients will have an indolent presentation (case 2) whilst some can have a much more florid presentation (case 3).
DIAGNOSIS
Whilst the presence of a deviation from the normally expected features of a condition should alert the clinician to the fact that a patient may have overlap, the patient should be viewed holistically and no single feature that differs from expected can be used as the sole basis for diagnosis of overlap. The most commonly used criteria in suspected PBC-AIH overlap was developed by Chazouillieres et al (3) ( Table 2) . Using these criteria, a diagnosis of overlap is proposed if a patient has two out of the three features of PBC as well as two out of three features of AIH. These criteria combine biochemical, immunological and histological features with biopsy being a mandatory requirement. Perhaps in a reflection of
an absent gold standard, these criteria are reported as having a high sensitivity (92%) and specificity (97%) for PBC-AIH overlap (6). antinuclear antibodies can be useful where there is diagnostic doubt (i.e. AMA negative disease) with anti-Sp100 and anti-gp210 having a high specificity for PBC (>95%). In addition, Nakamura et al (7) demonstrated that anti-gp210 positivity was an independent risk factor for progressive disease (including end stage hepatic failure, hepatocellular carcinoma and variceal bleeding) and liver transplant and that biopsies from these patients typically showed severe interface hepatitis and lobular inflammation. This phenotype can often be confused for PBC-AIH overlap. However, gp210 positivity is a marker of a poor response to steroids (8) . The significance of anti sp100 positivity is less well understood but is also thought to be associated with more rapidly progressive disease (9) .
TREATMENT
Whilst PBC and AIH both fall under the umbrella term of autoimmune liver disease, their treatment strategies are distinct. Currently, ursodeoxycholic acid (UDCA) is the only treatment licensed for use in PBC (where it is given at a dose of 13-15mg/kg/day), and the mainstay of treatment for AIH is immunosuppression initially with corticosteroids, and subsequently azathioprine. There is a paucity of randomised data to guide treatment guidelines for overlap.
In practice, treatment is commonly guided by the mode of presentation with different strategies employed for those with simultaneous presentations than for those with distinct sequential presentations. In a patient who has overt features of both PBC and AIH at first presentation it is often best to treat with UDCA for six months and then re-evaluate, with response. Exclusion of drug induced liver injury is important, as is identification of AMA negative PBC. The latter group were classically first described as 'autoimmune cholangitis' precisely because they had elevated IgG values and were AMA negative (10).
WHEN TO REFER FOR SPECIALIST OPINION
Due to the lack of specific diagnostic criteria for overlap, the variety of modes of presentation and the relative rarity of the condition, it can often be difficult to positively or negatively determine the diagnosis of an overlap syndrome. This can lead to under treatment with the risk of uncontrolled disease progressing to fibrosis and cirrhosis or over diagnosis leading to patients receiving escalating immunosuppression and the associated risk of treatment side effects. Referral to a specialist centre with a high volume caseload of patients with autoimmune liver disease should be considered in the following circumstances:
• Patients with UDCA unresponsive disease 
TAKE HOME MESSAGES
• Suspect the diagnosis of overlap in any patient with features of more than one condition either at diagnosis or over the disease course.
• There is no single diagnostic feature for overlap and the patient should be viewed individually, over time, with a focus on the dominant histologic process in particular.
• Be cautious when diagnosing overlap in the young patient with PBC and inflammatory features on biochemistry and histology.
• Liver biopsy, with review by a specialist histopathologist, is essential in the evaluation of overlap presentations.
• If in doubt, refer to a multi-disciplinary expert team for advice.
• Be cognisant that age, gender and ethnicity can impact disease presentation in autoimmune liver disease. Autoantibody screen showed a positive AMA, SMA was negative and IgG was within normal range. She was diagnosed with PBC and commenced on UDCA. After 4 months of treatment with UDCA her ALP remained raised at 379 and her ALT was mildly elevated at 56. She underwent a liver biopsy which showed interface activity and portal inflammation. She was given a diagnosis of overlap syndrome and was commenced on prednisolone but this was stopped after three months. This was followed by a further rise in ALT to 97. As such, prednisolone was restarted and azathioprine added. Despite remaining on prednisolone 20mg and azathioprine being titrated up to 1.5mg/kg/day her ALT remained raised. Her prednisolone was further increased to 30mg and she was referred for tertiary opinion. At this time, she was symptomatic from her steroid use. Her original biopsy was reviewed and whilst it was felt that inflammatory activity was present this could be consistent with biliary disease. Extended serology showed positive ANA 1:100 (multidot pattern), sp100 positive, gp210 negative. The overall impression was that this was not overlap and immunosuppression was withdrawn and UDCA was continued. The patient's biochemistry remained abnormal and she is likely to progress to transplant unless new therapies emerge.
Learning points: this case illustrates a young patient who met diagnostic criteria for PBC but with some features that are inconsistent with classic PBC. It is recognised that patients diagnosed with PBC before the age of 50 have a 50% chance of being UDCA treatment nonresponders and that non-response is frequently characterised on the basis of elevated serum aminotransferase activity (11). These patients, sometimes referred to as hepatitic 
Case 2
Mrs. B was diagnosed at the age of 58 with PBC. Extended serology showed AMA positivity (titre 1:100), ANA negative, sp100 and gp210 negative with a normal IgG and raised IgM. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Biopsy was consistent with AIH with confluent/bridging necrosis, plasma cells, interface hepatitis and rosettes. She remained on UDCA and was started on prednisolone 20mg with the addition of azathioprine 50mg once biochemical response to steroids was achieved and titrated to a dose of 150mg. The patient achieved normal tests.
Learning points: this case illustrates a consecutive diagnosis of two diagnoses (PBC followed by AIH) which is the most common type of overlap seen in the outpatient setting. Given the time separating the presentations, it is appropriate to investigate the new liver biochemical changes as for any patient; viral screen, drug screen, autoimmune screen. In this case there were clear features of AIH and treatment was commenced as per standard guidelines.
Case 3
Mrs. C had a known diagnosis of PBC and was on treatment with UDCA at a dose of 1000mg daily. In late 2014 she presented for her routine out patient follow up and was found to be response to UDCA treatment suggests that this is a hepatitic PBC rather than overlap.
Question 2
Mrs. D was diagnosed with PBC at the age of 52 and commenced on UDCA at a dose of 14mg/kg/day. After nine months of treatment her liver biochemistry was entirely normal.
She is reviewed in clinic on an annual basis. At a routine follow up she is noted to be This scenario describes a patient with established PBC who develops a new onset jaundice with a predominantly hepatitic pattern. All of the above conditions can cause a hepatitic jaundice. AST is higher than ALT and MCV is raised which could suggest alcoholic hepatitis.
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